Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05970510
PHASE3

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

Sponsor: Luye Pharma Group Ltd.

View on ClinicalTrials.gov

Summary

The study aims to evaluate the efficacy and safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets compared to placebo in adults participants with generalized anxiety disorder over a period of 8 weeks.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Participants With Generalized Anxiety Disorder.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

555

Start Date

2023-07-12

Completion Date

2026-04-30

Last Updated

2024-03-15

Healthy Volunteers

No

Interventions

DRUG

Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg

orally once a day

DRUG

Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg

orally once a day

DRUG

placebo

orally once a day

Locations (1)

Peking University Sixth Hospital

Beijing, China